Abstract
No public abstract is available from the verified source records.
Suchita Sampath, Joy Mosser-Goldfarb
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global burden of atopic dermatitis: examining disease prevalence across pediatric and adult populations world-wide
10.1016/j.det.2024.05.004 · 2024
Persistence of atopic dermatitis (AD): a systematic review and meta-analysis
10.1016/j.jaad.2016.05.028 · 2016
Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis
10.1001/jamadermatol.2018.1572 · 2018
Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines
10.1111/pde.15327 · 2023
The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review
10.1080/09546634.2023.2292962 · 2024
Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial
10.1093/bjd/ljad281 · 2023
Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents
10.1016/j.jaad.2014.03.030 · 2014
Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial
10.1016/s0140-6736(06)68340-2 · 2006
New and emerging trends in the treatment of atopic dermatitis
2008
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
10.1111/bjd.19574 · 2021
Comparative efficacy and safety of tralokinumab and dupilumab in moderate-to-severe atopic dermatitis: a narrative review
10.3390/jcm14144960 · 2025
Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-Week, open-label, phase 3 study
10.1007/s13555-023-00942-y · 2023
Lebrikizumab vs other systemic monotherapies for moderate-to-severe atopic dermatitis: network meta-analysis of efficacy
10.1007/s13555-025-01357-7 · 2025
Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: a systematic review and network meta-analysis
10.1371/journal.pone.0319400 · 2025
Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study
10.1093/bjd/ljad268 · 2024
Practical recommendations on laboratory monitoring in patients with atopic dermatitis on oral JAK inhibitors
10.1007/s13555-024-01243-8 · 2024
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
10.1016/s0140-6736(20)30732-7 · 2020
Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials
10.1001/jamadermatol.2023.0391 · 2023
Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update
10.1001/jamadermatol.2024.2192 · 2024
Pediatric allergic contact dermatitis. Part I: clinical features and common contact allergens in children
10.1016/j.jaad.2020.11.002 · 2021
Characterization of pediatric patch testing: a retrospective review, 2020-2023
10.1089/derm.2024.0005 · 2024
Pediatric patch testing at Mayo clinic between 2016 and 2020
10.1089/derm.2023.0353 · 2024
Atopic dermatitis-like genodermatosis: disease diagnosis and management
10.3390/diagnostics12092177 · 2022
Children atopic dermatitis: diagnosis, mimics, overlaps, and therapeutic implication
10.1111/dth.15901 · 2022
Generalised eczema: a diagnostic clue to Wiskott-Aldrich syndrome
10.1136/bcr-2021-242642 · 2021
Dupilumab successfully controlled eczema in Wiskott-Aldrich syndrome over 52 weeks
10.1038/s41390-025-03941-1 · 2025
Netherton syndrome
10.1001/jamadermatol.2022.3796 · 2022
Netherton syndrome in children: management and future perspectives
10.3389/fped.2021.645259 · 2021
Treatment of Netherton syndrome with dupilumab
10.1001/jamadermatol.2019.4608 · 2020
Acrodermatitis enteropathica and an overview of zinc metabolism
10.1016/j.jaad.2006.08.015 · 2007
Acrodermatitis enteropathica
10.1016/s0738-081x(00)00150-4 · 2000
Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management
10.1111/ijd.16098 · 2022
Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis
10.1016/j.jaad.2017.05.059 · 2018
No additional external references are available.